Novo’s oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

Plus, news about Ar­row­head, Cul­li­nan Ther­a­peu­tics, Cy­to­ki­net­ics, Zen­tal­is, In­ovio and Mind Med­i­cine: Do­mes­tic biotech M&A in Chi­na: North­east Phar­ma­ceu­ti­cal Group, a decades-old mak­er of gener­ics

Bio­haven’s ex­per­i­men­tal drug tro­r­ilu­zole for the rare, neu­rode­gen­er­a­tive dis­ease spin­ocere­bel­lar atax­ia will get a pri­or­i­ty re­view from the FDA, af­ter the com­pa­ny pre­sent­ed ad­di­tion­al re­al

MK-6070 was acquired by MSD through its purchase of Harpoon Therapeutics. Credit: Merck & Co., Inc., Rahway, NJ USA, and its affiliates. Daiichi Sankyo and